## IDXX: IDEXX Laboratories, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.3% below STRENGTH zone (3.0-6.0%); PEG 4.06 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-6.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($676.55)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 5, Bearish: 0)

**1. Arrowstreet Capital Limited Partnership Acquires 15,227 Shares of IDEXX Laboratories, Inc. $IDXX**
- Source: MarketBeat | 20251204T090925 | Somewhat-Bullish | Relevance: 100%
- Arrowstreet Capital Limited Partnership increased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.0%, acquiring an additional 15,227 shares to hold a total of 206,137 shares valued at $110.56 million. This comes as analysts have raised price targets for IDEXX, with a consensus of "Moderate Buy" and an average target price of $730.50. Meanwhile, insider activity shows EVP Nimrata Hunt selling 9,425 shares, reducing her ownership by over 30%.

**2. How Is IDEXX Laboratories’ Stock Performance Compared to Other Health Care Stocks?**
- Source: Markets Financial Content | 20251204T022900 | Bullish | Relevance: 100%
- IDEXX Laboratories, Inc. (IDXX), a leader in veterinary diagnostics, has shown strong stock performance, outperforming the Health Care Select Sector SPDR Fund (XLV) over the past three months, year-to-date, and the last 52 weeks. The company's Q3 results exceeded expectations, leading to raised full-year guidance and highlighting its robust business model and market position. Despite strong performance, analysts maintain a cautiously optimistic "Moderate Buy" rating with a price target suggesting further upside.

**3. How Is IDEXX Laboratories’ Stock Performance Compared to Other Health Care Stocks?**
- Source: Markets Financial Content | 20251204T022900 | Bullish | Relevance: 100%
- IDEXX Laboratories (IDXX) is a global leader in veterinary diagnostics, consistently outperforming the Health Care Select Sector SPDR Fund (XLV) and rival Zoetis Inc. (ZTS) over several periods. The company's strong performance is driven by a diversified product ecosystem, recurring revenue model, and robust R&D, leading to increased full-year guidance and a "Moderate Buy" consensus rating from analysts.

**4. IDEXX Laboratories Stock Rallies 75.6% YTD: What's Behind the Surge?**
- Source: Eastern Progress | 20251204T190752 | Bullish | Relevance: 100%
- IDEXX Laboratories (IDXX) stock has rallied 75.6% year-to-date, outperforming its industry and the S&P 500, driven by strong strategic execution, new business gains, and high customer retention. The company's Companion Animal Group Diagnostics segment shows particular strength, with recurring revenue growth exceeding sector levels both domestically and internationally. Cloud-based products and an expanding pet owner engagement application are also contributing significantly to its growth.

**5. Veterinary Software Market Set to Witness Significant Growth by 2025-2032 | Idexx Laboratories, Covetrus Inc., Asteris**
- Source: EIN News | 20251202T135141 | Bullish | Relevance: 100%
- The Veterinary Software Market is projected to grow significantly, reaching USD 2.20 billion by 2032 from USD 1.33 billion in 2025, with a CAGR of 7.4%. A new report from Coherent Market Insights details this growth, driven by key factors, market participants like Idexx Laboratories and Covetrus Inc., and segmented analysis by product type, application, end-user, and region. The report also highlights competitive analysis, key strategic developments, and regional growth opportunities within the sector.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 4, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-04 | Morgan Stanley | $805 | $765 | +5% |
| 2025-11-04 | UBS | $750 | $710 | +6% |
| 2025-11-04 | JP Morgan | $775 | $675 | +15% |
| 2025-11-04 | BTIG | $830 | $785 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-04 | Morgan Stanley | main | Overweight |
| 2025-11-04 | UBS | main | Neutral |
| 2025-11-04 | JP Morgan | main | Overweight |
| 2025-11-04 | BTIG | main | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 3 ($2.08M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 44.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 12.5% (+0.9%)
- Blackrock Inc.: 10.3% (-2.0%)
- State Street Corpora: 4.4% (-1.0%)
- Fundsmith LLP: 3.3% (-1.1%)
- Geode Capital Manage: 3.1% (+1.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-6.5% 5d) with bearish MACD, trend may be turning.
2. Valuation stretched: PEG 4.1x requires aggressive growth execution.
3. Market regime shift could impact high-beta names disproportionately.

### Catalysts

- Analyst target momentum: 4 raises (avg +8%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.06 signals overvaluation risk, limited margin of safety. Forward P/E 49.8x stretched relative to 12% growth. Quality metrics strong (ROE 65%, ROA 24%, margin 25%). Analyst sentiment positive (4 raises, avg +8%). Insider buying signal ($2.1M), management confidence. Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $55.1B |
| Beta | 1.67 |
| 52W Range | $356.14 - $769.98 |
| Short Interest | 3.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.06 |
| Forward P/E | 49.8 |
| Current P/E | 55.6 |
| YoY Growth | 11.7% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from 2.2% to -4.3% (-6.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.3pp (needs >3.0% for momentum thesis). Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.87), momentum weakening. RSI neutral at 54. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.27% (CS: 9) | Weak |
| RSI_14 | 53.7 | Neutral |
| MACD Histogram | -1.87 | Bearish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 1.068x | Above |
| vs SMA200 | 1.286x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $717.47
- **Stop Loss:** $676.55 (5.7% risk)
- **Target:** $758.39 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 12
- **Position Value:** $8,609.64
- **Portfolio %:** 8.61%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-03 (Est: $2.93)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.14 | $3.40 | +8.3% |
| 2025Q2 | $3.30 | $3.63 | +10.0% |
| 2025Q1 | $2.85 | $2.96 | +3.9% |
| 2024Q4 | $2.40 | $2.62 | +9.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*